Curia, Inc

The primary objective is to evaluate the effect of pozelimab + cemdisiran on daily functioning affected by signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG). The secondary objectives of this study are to evaluate the effects of pozelimab + cemdisiran (i.e., combination therapy) and cemdisiran monotherapy on the following aspects: Clinician-assessed signs and strength of myasthenia gravis (MG); Daily functioning affected by signs and symptoms in patients with symptomatic gMG (cemdisiran monotherapy alone); The proportion of patients with improvement in daily functioning affected by MG signs and symptoms; The proportion of patients with improvement in MG signs and strength as assessed by clinicians; Health-related quality of life; The proportion of patients with minimal MG symptoms; Patient- and clinician-reported signs and symptoms of MG. 2. Evaluate the safety and tolerability of pozelimab + cemdisiran combination therapy and cemdisiran monotherapy. 3. Evaluate the concentration of total pozelimab in serum 4. Evaluate the concentration of total C5 in plasma 5. Evaluate the concentration of cemdisiran and its metabolites in plasma 6. Evaluate the immunogenicity of pozelimab 7. Evaluate the immunogenicity of cemdisiran 8. Study the effects of pozelimab + cemdisiran combination therapy and cemdisiran monotherapy on complement activation